Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients

• Status: Completed
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to evaluate the effect of ARB in improving insulin secretion in patients with type 2 diabetes. The investigators also aimed to evaluate if there are potential synergisms between ARB and DPP4 inhibitors in improving insulin secretion and urinary albumin secretion in diabetic patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Amlodipine

Criteria

Inclusion Criteria:

• Aged 20~80 years

• Type 2 diabetic patients diagnosed more than 6 months ago

• HbA1c ≤8.5% at screening

• No change of OAD within the 3 months before screening

• SBP <140 mmHg and DBP <90 mmHg with anti-hypertensive drug at screening

• SBP ≥140 mmHg or DBP ≥80 mmHg without anti-hypertensive drug at screening

Exclusion Criteria:

• Type 1 diabetic patients or active insulin treatment at screening

• Treatment with ARB or ACEi within 1 month prior to screening

• Uncontrolled hypertension with SBP >170 mmHg or DBP >100 mmHg

• Pregnancy or lactation

• Elevated liver enzyme (AST or ALT > 3 times the UNL) or elevated serum Cr (≥1.5 mg/dL in men and 1.4 mg/dL in women)